Menu
Search
|

Menu

Close
X

Concert Pharmaceuticals Inc CNCE.OQ (NASDAQ Stock Exchange Global Market)

19.37 USD
-0.27 (-1.37%)
As of Jun 22
chart
Previous Close 19.64
Open 19.67
Volume 353,449
3m Avg Volume 89,049
Today’s High 19.85
Today’s Low 19.12
52 Week High 30.70
52 Week Low 12.67
Shares Outstanding (mil) 22.69
Market Capitalization (mil) 347.34
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
10
FY17
144
FY16
0
FY15
67
EPS (USD)
FY18
-0.192
FY17
3.986
FY16
-2.281
FY15
0.955
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
4,235.86
5.71
Price to Book (MRQ)
vs sector
5.38
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
45.34
16.46
LT Debt to Equity (MRQ)
vs sector
45.34
12.19
Return on Investment (TTM)
vs sector
-45.62
14.38
Return on Equity (TTM)
vs sector
-58.35
16.08

EXECUTIVE LEADERSHIP

Richard Aldrich
Chairman of the Board, Co-Founder, Since 2006
Salary: --
Bonus: --
Roger Tung
President, Chief Executive Officer, Co-Founder, Director, Since 2006
Salary: $409,565.00
Bonus: --
Ryan Lynch
Principal Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Marc Becker
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Nancy Stuart
Chief Operating Officer, Since 2007
Salary: $329,741.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

99 Hayden Ave Ste 500
LEXINGTON   MA   02421-7966

Phone: +1781.8600045

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

SPONSORED STORIES